GlassScriptPhysician profile
Claudette M Johns
NPI 1720474026
$6,526.83
in general payments reported to CMS, 2019-2025
25 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,617 · 2022: $1,117 · 2023: $1,630 · 2024: $1,073 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.52 |
| Education | $130.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,722.50 | 2021-2025 | Biktarvy, Descovy |
| Viiv Healthcare Company | $1,138.44 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $790.91 | 2021-2025 | |
| Janssen Products, LP | $618.34 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $452.79 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Glaxosmithkline, LLC. | $364.57 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Biotech, INC. | $351.87 | 2021-2023 | Symtuza |
| Astellas Pharma US INC | $201.24 | 2023 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $182.10 | 2022-2024 | Airsupra, Farxiga |
| Theratechnologies INC. | $167.00 | 2021-2023 | Egrifta Sv, Egrifta, Trogarzo |
| Abbott Laboratories | $71.28 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $70.31 | 2022-2024 | |
| Amgen INC. | $62.10 | 2021-2023 | Repatha |
| Vanda Pharmaceuticals INC. | $56.23 | 2021 | |
| Exact Sciences Corporation | $51.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $33.26 | 2022-2023 | Doc Band |
| Hologic Sales and Service, LLC | $32.40 | 2022-2023 | Thinprep 2000 Processor, Aptima |
| Teva Pharmaceuticals USA, INC. | $26.49 | 2025 | Ajovy |
| Lilly USA, LLC | $24.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.94 | 2024 | |
| Sunovion Pharmaceuticals INC. | $21.68 | 2021 | |
| Csl Behring | $19.46 | 2024 | Kcentra, Haegarda |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.66 | 2022 | |
| Alk-Abello, INC | $14.45 | 2023 | Grastek, Ragwitek, Odactra |
| Therapeuticsmd, INC. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudette Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.